

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

VOLUNTARY ANNOUNCEMENT IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT WITH BAIYUNSHAN

The board of directors (the “**Board**”) of Alibaba Health Information Technology Limited (the “**Company**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) that the Company entered into a framework agreement on January 13, 2015 with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.* (廣州白雲山醫藥集團股份有限公司) (“**Baiyunshan**”) to pursue strategic cooperation in the pharmaceutical and healthcare sectors (the “**Strategic Cooperation Framework Agreement**”).

The Strategic Cooperation Framework Agreement, provides, among other things, that the Company and Baiyunshan intend to cooperate in the following areas:

- (i) **Pharmaceutical e-commerce:** To leverage on the Company’s platform and technical resources, as well as Baiyunshan’s wide range of pharmaceutical products, large retail network and mature pharmacy outsourcing technology, to jointly explore and develop an “online to offline” or “O2O” business model for the sale of pharmaceutical products.
- (ii) **General healthcare products:** To integrate Baiyunshan’s existing health products with the Company’s platform, and to jointly develop specific products based on the Company’s healthcare big data.
- (iii) **Medical and healthcare services:** To combine the Company’s technology and platform with Baiyunshan’s medical resources to jointly develop “hospitals for the future”, explore and develop new businesses, and explore new operational models that provide wider community circulation of hospital prescriptions.

Baiyunshan is a renowned state-owned company listed on both Main Board of the Stock Exchange of Hong Kong Limited (Stock Code 00874) and Shanghai Stock Exchange (Stock Code SH600332), principally engaged in the research, manufacturing and sales of pharmaceutical and healthcare products. To the best of the knowledge, information and belief having made all reasonable enquiries by the directors of the Company, Baiyunshan and their ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

Shareholders of the Company and/or potential investors are advised to exercise caution when dealing in the shares of the Company

By Order of the Board
Alibaba Health Information Technology Limited
WANG Jian
Chairman of the Board

Hong Kong, January 15, 2015

As at the date of this announcement, the Board comprises nine directors, of which (i) two are executive Directors, namely Dr. WANG Jian and Ms. CHEN Xiao Ying; (ii) four are non-executive Directors, namely Mr. ZHANG Yong, Mr. CHEN Jun, Mr. CHIA Pun Kok and Mr. YU Feng; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.

* *For identification purpose only*